Discovery and clinical validation of cost-effective noninvasive early detection of hepatocellular carcinoma (HCC) through circulating tumor DNA (ctDNA) methylation signature

MLA

Xin-Rong Yang, et al. “Discovery and Clinical Validation of Cost-Effective Noninvasive Early Detection of Hepatocellular Carcinoma (HCC) through Circulating Tumor DNA (CtDNA) Methylation Signature.” Journal of Clinical Oncology, vol. 40, June 2022, p. 4103. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.4103.

APA

Xin-Rong Yang, Rui Liu, Jian Zhou, Jia Fan, De-Zhen Guo, Ao Huang, Yingchao Wang, Zhixiong Cai, Hui Wang, Qichang Yang, Zhixi Su, Chengcheng Ma, Minjie Xu, & Wei Li. (2022). Discovery and clinical validation of cost-effective noninvasive early detection of hepatocellular carcinoma (HCC) through circulating tumor DNA (ctDNA) methylation signature. Journal of Clinical Oncology, 40, 4103. https://doi.org/10.1200/jco.2022.40.16_suppl.4103

Chicago

Xin-Rong Yang, Rui Liu, Jian Zhou, Jia Fan, De-Zhen Guo, Ao Huang, Yingchao Wang, et al. 2022. “Discovery and Clinical Validation of Cost-Effective Noninvasive Early Detection of Hepatocellular Carcinoma (HCC) through Circulating Tumor DNA (CtDNA) Methylation Signature.” Journal of Clinical Oncology 40 (June): 4103. doi:10.1200/jco.2022.40.16_suppl.4103.